Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Diazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 8/20 | 0.93 |
| ▸ | GABRG2 known ✓ | P18507 | 8/20 | 0.93 |
| ▸ | GABRB3 known ✓ | P28472 | 8/20 | 0.93 |
| ▸ | GABRA5 known ✓ | P31644 | 8/20 | 0.93 |
| ▸ | GABRA3 known ✓ | P34903 | 8/20 | 0.93 |
| ▸ | GABRA2 known ✓ | P47869 | 8/20 | 0.93 |
| ▸ | GABRB2 known ✓ | P47870 | 5/20 | 0.93 |
| ▸ | GABRP known ✓ | O00591 | 2/20 | 0.93 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.93 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.93 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.93 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 0.93 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.93 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 2/20 | 0.93 |
| ▸ | GABRG3 known ✓ | Q99928 | 2/20 | 0.93 |
| ▸ | GABRQ known ✓ | Q9UN88 | 2/20 | 0.93 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.93 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.93 |
| ▸ | ALB | P02768 | 1/20 | 0.93 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diazepam SCHEMBL28100552 | 0.96 | GABRA1 (0.95) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL29362687 | 0.96 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL9278054 | 0.96 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL21442 | 0.96 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL1019217 | 0.96 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL16922183 | 0.96 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL3044828 | 0.95 | GABRA1 (0.93) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL3043280 | 0.95 | GABRA1 (0.97) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL4370625 | 0.95 | GABRA1 (0.97) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Diazepam SCHEMBL6014348 | 0.95 | GABRA1 (0.97) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153142-B2 | Skin treatment composition | SHISEIDO CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20100209370-A1 | Skin treatment composition | BUXOM US BUYER LLC | 2010-08-19 | — | — | US | disclosed |
| US-20100209701-A1 | METHOD FOR MANUFACTURING TRANSPARENT PLASTIC FILM AND TRANSPARENT PLASTIC FILM MANUFACTURED BY THE METHOD | LG CHEM, LTD. (KR) | 2010-08-19 | — | — | US | disclosed |
| EP-1283031-B1 | Skin treatment composition comprising a polyoxyethylene polyoxyalkylene dialkyl substituted ether | SHISEIDO CO LTD (JP) | 2008-01-02 | — | — | EP | disclosed |
| US-20030198614-A1 | Hair growers | SHISEIDO CO., LTD. (JP) | 2003-10-23 | — | — | US | disclosed |
| US-20030180335-A1 | Skin treatment composition | BUXOM US BUYER LLC | 2003-09-25 | — | — | US | disclosed |
| EP-1314417-A1 | HAIR GROWERS | Shiseido Co., Ltd. (JP) | 2003-05-28 | — | — | EP | disclosed |
| EP-1283031-A2 | Skin treatment composition | Shiseido Co., Ltd. (JP) | 2003-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030180335-A1 | Skin treatment composition | OXER1, CUTA, HRH2 | GABRA1 3950/4885GABRG2 4217/4885GABRB3 3911/4885 |
| US-20030198614-A1 | Hair growers | EBP, FGF1, HSD17B7 | GABRA1 4487/4885GABRG2 3996/4885GABRB3 3677/4885 |
| US-20100209370-A1 | Skin treatment composition | CUTA, OXER1, HRH2 | GABRA1 4320/4885GABRG2 4367/4885GABRB3 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.